Seven of the eleven patients (63%) patients with both thyroid and breast cancer had a CHEK2 mutation, compared to 16% (73/468) of the thyroid cancer patients without breast cancer (p < 0.001). This evidence concerns the gene CHEK2 and breast carcinoma.